Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Blautia wexlerae Transforms Dietary Fatty Acids to Activate Enteroendocrine Signaling and Improve Metabolic Health in Mice and Humans.
Journal: bioRxiv : the preprint server for biology
Published: April 10, 2026
Effect of Esophageal Dilation History on Efficacy Outcomes in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension.
Journal: The American journal of gastroenterology
Published: May 30, 2024
Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Participants: A Randomized Phase 1 Study.
Journal: Journal of clinical pharmacology
Published: April 12, 2024
Effect of randomized treatment withdrawal of budesonide oral suspension on clinically relevant efficacy outcomes in patients with eosinophilic esophagitis: a post hoc analysis.
Journal: Therapeutic advances in gastroenterology
Published: February 29, 2024
Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis.
Journal: Journal of pediatric gastroenterology and nutrition
Published: September 18, 2023
Editorial: safety of topical steroids designed specifically for eosinophilic oesophagitis - new data bring new questions. Authors' reply.
Journal: Alimentary pharmacology & therapeutics
Published: April 24, 2023
Qualitative assessment of the suitability of the Dysphagia Symptom Questionnaire to monitor dysphagia in children aged 7-10 years with eosinophilic esophagitis.
Journal: Journal of patient-reported outcomes
Published: January 10, 2023
Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1-3 clinical trials.
Journal: Alimentary pharmacology & therapeutics
Published: September 21, 2022
Pharmacokinetics of Budesonide Oral Suspension in Children and Adolescents With Eosinophilic Esophagitis.
Journal: Journal of pediatric gastroenterology and nutrition
Published: June 06, 2022
Maralixibat for the treatment of PFIC: Long-term, IBAT inhibition in an open-label, Phase 2 study.
Journal: Hepatology communications
Published: January 20, 2022
Last Updated: 09/26/2026